The Shuman Law Firm Investigates Dynavax Technologies Corp.

The Shuman Law Firm announces that it is investigating potential claims against certain officers and directors of Dynavax Technologies Corp. (“Dynavax” or the “Company”) (Nasdaq: DVAX). Dynavax is a California based clinical-stage biopharmaceutical company.

The Firm’s investigation relates to potential damages to Dynavax caused by allegedly false and misleading public statements by the Company’s senior officers and directors regarding Dynavax’s Hepatitis B vaccine, “HEPISLAV”. These alleged false and misleading statements, when made public, led to the drop in Dynvax’s stock price and the filing of a class action lawsuit against the Company. Recently, a federal judge denied, in part, the Company’s motion to dismiss the class action lawsuit and the case is now proceeding toward trial.

If you currently own Dynavax common stock and are interested in discussing your rights, or have information relating to this investigation, please contact Kip B. Shuman or Rusty E. Glenn toll-free at [phone] or email Mr. Shuman at [e-mail] or email Mr. Glenn at [e-mail].

The Shuman Law Firm represents investors throughout the nation, concentrating its practice in stockholder litigation.

The Shuman Law FirmKip B. Shuman, Esq., [e-mail] E. Glenn, Esq., [e-mail]-Free: 866-569-4531Fax: [phone]www.shumanlawfirm.com